Skip to main content
. 2022 Jul 28;13:912005. doi: 10.3389/fimmu.2022.912005

Table 2.

Decrease in NFL level in response to disease-modifying therapies.

Reference # DMT QR-NFL
(88) Natalizumab 37%
(95) IFN or glatiramer acetate switch to rituximab 21%
(90) Natalizumab 20%
(89) Fingolimod 33%
(85) Natalizumab <16 pg/mL
(15) Fingolimod vs IFNβ1α 38%
(94) Ibudilast ND

ND, No difference; QR-NFL, quantitative reduction in NFL.